KALA BIO INC
KALANASDAQ🏆 #3640 by market capUS Equity
$112.16▲ $4.14 (+3.69%)
Simulated price1h—
24h▲ 3.7%
7d▲ 15723.9%
14d▲ 17023.7%
30d▲ 10285.2%
1y▼ 70.1%
🏦Market Cap
$15M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
31.0%
Moderate
💵FCF Margin
—
⚖️P/S Ratio
2.5x
Cheap
Otter Score
60
Fair
Trading Snapshot
- Day Range
- $110.60 – $113.76
- 52-Week Range
- $0.59 – $1,030.00
- Volume
- $3.37B
- Avg Volume
- $4.43B
- Shares Outstanding
- 19.3M
- Next Earnings
- Oct 1, 2026
Fundamentals Snapshot
- Annual Revenue
- $6M
- Last Q Revenue
- $1M
- P/E Ratio
- —
- P/S Ratio
- 2.5x
- EPS (TTM)
- $-136.77
- Dividend Yield
- —
Why Investors Own KALA
- ✓High-growth profile — revenue up +13.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 67% gross margin and 24% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$6M▲ +10.0% YoY
Gross Margin (TTM)
66.7%▲ +4.0% YoY
Operating Income (TTM)
$1M▲ +10.0% YoY
Free Cash Flow (TTM)
$1M▲ +10.0% YoY
About KALA BIO INC
A company profile for KALA BIO INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Fair
60/100
Analyst Price Target
ⓘAverage Target
$136.84
▲ +22.0% Upside
High Target$159.48
Low Target$108.36
Based on 27 analysts
Latest News & Updates
🚀
CNBC·2h ago
KALA BIO INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
CNBC·5h ago
Analysts lift KALA price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
MarketWatch·1d ago
KALA BIO INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.